A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
Completed · Phase 1 · NCT05935033
Conditions: Hepatic Impairment
At a glance
- Research payments reported, 2025
- $347,268
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 38
About the trial
- Sponsor
- AbbVie
- Tested
- Emraclidine (drug)
- Dates
- Started 2023-06-30; completion 2025-02-21
- Results posted
- Not yet
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
From ClinicalTrials.gov, last updated 2025-04-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $347,268 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thomas C. Marbury, M.D. Nephrology (Kidney) · Orlando, FL
- Richard A. Preston, MD, MBA Clinical Pharmacology · Miami, FL
- Eric J. Lawitz, M.D. Gastroenterology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Services Inc $206,294
- American Research Corporation $106,778
- Orlando Clinical Research $30,742
- Orlando Clinical Research Center $3,455
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.